Is PHASQ or ADC a better dividend investment in 2026?

PHASQ currently yields 200000000.00% with a 5% 5-year dividend growth rate. ADC yields 4.13% with 5.2% growth. The better choice depends on your goal: PHASQ offers higher current income.

What is the dividend yield difference between PHASQ and ADC?

PHASQ has a forward dividend yield of 200000000.00% ($2.00/share annually). ADC yields 4.13% ($3.10/share annually). The yield gap is 199999995.87 percentage points.

Home › Compare › PHASQ vs ADC

PHASQ vs ADC: Dividend Comparison 2026

PHASQ yields 200000000.00% · ADC yields 4.13%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 PHASQ wins by $4.875657285131069e+59M in total portfolio value

INVESTMENT

TIME HORIZON10 years

PHASQ

● Live price

200000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.875657285131069e+59M

Annual income

$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00

Full PHASQ calculator →

ADC

Agree Realty Corporation

● Live price

4.13%

Share price

$74.97

Annual div

$3.10

5Y div CAGR

40.4%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$178.9K

Annual income

$80,797.29

Full ADC calculator →

Portfolio growth — PHASQ vs ADC

📍 PHASQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	PHASQ	ADC
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, PHASQ + ADC cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

PHASQ pays

ADC pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PHASQ

Annual income on $10K today (after 15% tax)

$17,000,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr

ADC

Annual income on $10K today (after 15% tax)

$351.36/yr

After 10yr DRIP, annual income (after tax)

$68,677.70/yr

At 15% tax rate, PHASQ beats the other by $414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PHASQ + ADC for your $10,000?

PHASQ: 50%ADC: 50%

100% ADC50/50100% PHASQ

Portfolio after 10yr

$2.4378286425655345e+59M

Annual income

$243,782,624,477,893,130,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

100.00%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

PHASQ

No analyst data

Altman Z

-42.8

Piotroski

2/9

ADC

Analyst Ratings

Strong

Buy

Hold

Consensus: Buy

Price Target

$81.06

+8.1% upside vs current

Range: $75.00 — $84.50

Altman Z

1.6

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PHASQ buys

ADC buys

No recent congressional trades found for PHASQ or ADC in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricPHASQADC

Forward yield	200000000.00% ✓	4.13%
Annual dividend / share	$2.00	$3.10 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	40.4% ✓
Portfolio after 10y	$4.875657285131069e+59M	$178.9K ✓
Annual income after 10y	$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00 ✓	$80,797.29
Total dividends collected	$4.875656971401711e+59M	$156.7K ✓
Payment frequency	quarterly	monthly
Sector	Stock	REIT

Year-by-year: PHASQ vs ADC ($10,000, DRIP)

Year	PHASQ Portfolio	PHASQ Income/yr	ADC Portfolio	ADC Income/yr	Gap
1← crossover	$20,000,010,700	$20,000,000,000.00	$10,990	$580.36	+$20000.00M → PHASQ
2	$37,383,218,970,104,910	$37,383,197,570,093,464.00	$12,301	$860.26	+$37383218970.09M → PHASQ
3	$65,303,942,472,059,150,000,000	$65,303,902,472,014,860,000,000.00	$14,104	$1,298.62	+$65303942472059152.00M → PHASQ
4	$106,615,009,060,306,890,000,000,000,000	$106,614,939,185,088,440,000,000,000,000.00	$16,691	$2,008.16	+$1.0661500906030689e+23M → PHASQ
5	$162,672,273,967,082,950,000,000,000,000,000,000	$162,672,159,889,023,270,000,000,000,000,000,000.00	$20,580	$3,205.09	+$1.6267227396708296e+29M → PHASQ
6	$231,966,340,306,755,300,000,000,000,000,000,000,000,000	$231,966,166,247,422,140,000,000,000,000,000,000,000,000.00	$26,754	$5,330.02	+$2.319663403067553e+35M → PHASQ
7	$309,138,182,305,146,600,000,000,000,000,000,000,000,000,000,000	$309,137,934,101,162,400,000,000,000,000,000,000,000,000,000,000.00	$37,196	$9,345.14	+$3.091381823051466e+41M → PHASQ
8	$385,031,777,252,258,400,000,000,000,000,000,000,000,000,000,000,000,000	$385,031,446,474,403,340,000,000,000,000,000,000,000,000,000,000,000,000.00	$56,244	$17,523.09	+$3.850317772522584e+47M → PHASQ
9	$448,184,411,799,345,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000	$448,183,999,815,344,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00	$94,286	$35,736.21	+$4.481844117993459e+53M → PHASQ
10	$487,565,728,513,106,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000	$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00	$178,949	$80,797.29	+$4.875657285131069e+59M → PHASQ

PHASQ vs ADC: Complete Analysis 2026

PHASQ — Stock

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Full PHASQ Calculator →

ADC — REIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →

📬

Get this PHASQ vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PHASQ vs SCHD PHASQ vs JEPI PHASQ vs O PHASQ vs KO PHASQ vs MAIN PHASQ vs NNN PHASQ vs EPRT PHASQ vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.